Status:

UNKNOWN

PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.

Lead Sponsor:

Gustave Roussy, Cancer Campus, Grand Paris

Conditions:

LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT

Eligibility:

All Genders

15-70 years

Phase:

PHASE3

Brief Summary

MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY (BEC REGIMEN) FOLLOWED BY STANDARD RADIOTHERAPY (70 Gy / 7 WEEKS) VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOL...

Eligibility Criteria

Inclusion

  • of either sex
  • aged \*15 and \* 70 years
  • never previously treated with radiotherapy, chemotherapy or surgery for malignant disease (except neck adenectomy/diagnosis)
  • with aWHO performance status \* 2.
  • amenable to regular follow-up
  • capable of receiving chemotherapy and radiotherapy : in particular, with no contraindications to the use of anthracyclines, bleomycin or cisplatinum.
  • with informed consent at entry time, in writing or witnessed oral informed consent, in accordance with local legislation requirements.
  • Laboratory requirement : \*Baseline hematologic status :
  • Neutrophil count \* 2000 /mm3 Platelet count \* 150,000 /mm3 Hemoglobin \* 10 g / dl

Exclusion

  • Histologic types other than type II - III of the WHO classification
  • T1 - T2 N0 - N1 or patients with metastatic
  • Aged \< 15 or \> 70.
  • Patients in whom chemotherapy is contraindicated: history of myocardial infarction over the last 6 months before inclusion, or clinically present cardiac pathology.
  • WHO Performance status \>2
  • History of prior malignancies (other than non melanoma skin cancer or excised cervical carcinoma in situ).
  • Uncontrolled infection,
  • Patients refusing participation.
  • Patients who, for social, familial or geographic reasons are unlikely to comply with a long term follow-up.

Key Trial Info

Start Date :

February 1 1995

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

520 Patients enrolled

Trial Details

Trial ID

NCT00180973

Start Date

February 1 1995

Last Update

September 16 2005

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Institut Gustave Roussy

Villejuif, France, 94800